TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \>=18 years of age~* Locally advanced or metastatic colorectal cancer~* No previous treatment with chemotherapy for metastatic disease~* Measurable and/or evaluable lesions~Exclusion Criteria:~* Radiotherapy within 4 weeks before study~* Untreated brain metastases or primary brain tumors~* Chronic, daily treatment with high-dose aspirin (\>325mg/day)~* Co-existing malignancies, or malignancies diagnosed within the last 5 years, with the exception of basal and squamous cell cancer, or cervical cancer in situ

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Scaling Up Science-based Mental Health Interventions in Latin America

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provider and administrative staff Inclusion Criteria:~  * Aged \> 18 years~ * Have worked for the study site for at least 3 months.~* Participant Inclusion Criteria:~  * Aged \> 18 years~ * Patients at one of our collaborating primary care sites~ * Screen positive for minor (score of 5-9), moderate (score of 10-14), moderately severe (score of 15-19) or severe (score of 20-27) depression on Patient Health Questionnaire (PHQ-9)62 and/or screen positive for problematic alcohol use on Alcohol Use Disorder Identification Test (AUDIT) developed by the World Health Organization (a score of 8 or more on 10-item AUDIT)63 and have a confirmed diagnosis of depression and/or alcohol use disorder based on clinical consultation at the primary care site~ * Willing to provide informed consent to use mobile intervention and complete study assessments~Exclusion Criteria:~-Participant Exclusion Criteria~* Diagnosis with co-occurring severe mental illness (e.g., schizophrenia, bipolar disorder, depression with psychotic features)~* Alcohol withdrawal symptoms that require higher level of care (e.g., emergency medical or inpatient treatment)~* Express suicidal intention. This assessment will be based on a combination of a patient's response on the PHQ-9 assessment followed by further assessment by a primary care clinician. The PHQ-9 measure will not be used solely to determine eligibility on this criterion. Persons who express suicidal intention will immediately be provided immediate crisis management in accordance with the crisis management protocol at the collaborating primary care site.~* Intoxicated or otherwise impaired at the time of assessment (rendering the individual incapable of informed consent)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Digital Health Assisted Mental Healthcare (Type: EXPERIMENTAL): This Digital Health Assisted Mental Healthcare intervention will be based on the novel mobile-based platform (Laddr® from Square2 Systems).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic or locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction~* No prior chemotherapy in metastatic state~* Adequate blood and biochemistry parameters~Exclusion Criteria:~* Hypersensitivity for 5-FU, Leucovorin, Oxaliplatin or Docetaxel~* KHK, cardiomyopathy or cardiac insufficiency~* Malignancy \<5 years ago~* Brain metastases~* Severe internal disease or inadequate blood and biochemistry parameters~* Pregnancy and lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FLOT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PUVA Maintenance Therapy in Mycosis Fungoides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathologically documented MF clinical stage IA-IIB (see Table1) confirmed by current or previous diagnostic lesion biopsy~* A Karnofsky performance score \> 60~* No previous PUVA treatment~* Anti-ds-DNA (antinuclear antibodies) or anti-Ro/La antibodies: negative~* Acceptable organ function defined as follows:~SGOT (AST) and SGPT (ALT) \< 2.5 times the upper limit of normal for the institution~* Creatinine \< 2 times the upper limit of normal for the institution~* No evidence of severe cardiac insufficiency (NYHA grade III-IV)~* Women of child bearing potential must have a negative serum pregnancy test (ß-HCG) within seven (7) days prior to randomization~* Absence of any serious intercurrent illness or infection at time of entry into the study that could interfere with planned treatment~* Patients must be willing to accept limiting sun exposure on the day receiving PUVA treatment~* Written informed consent~Exclusion Criteria:~* Pregnancy and Lactation~* Photosensitive diseases such as lupus erythematosus or basal cell nevus syndrome~* Skin cancer syndromes such as xeroderma pigmentosum or basal cell nevus syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 82 Years
- Healthy Volunteers: f

Study Arms:
- PUVA maintenance treatment (Type: ACTIVE_COMPARATOR): Psoralen plus UVA (PUVA) treatment. The patients receive a standardized dose of oral 8-methoxypsoralen (Oxsoralen) 1 hour before UVA exposure
- No maintenance treatment (Type: NO_INTERVENTION): observation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Steroid-Antiviral Treatment in Rehabilitation of Facial Palsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute onset facial palsy within the first three days of onset. Age ranged from 15-60 years old~Exclusion Criteria:~* Patients with brittle diabetes mellitus, Morbid obesity, renal or liver impairment, osteopenia, prior history of steroid intolerance.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Steroid Group (Type: ACTIVE_COMPARATOR): prednisolone 60 mg /day IM /IV for 6 consecutive days then reduced by 10 mg /day (for a total treatment time for 12 days)
- Steroid + Antiviral Group (Type: ACTIVE_COMPARATOR): Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic, genotype 1, hepatitis C with detectable HCV RNA~* HIV-1 infection for \>6 months~* Documentation of a liver biopsy within 1 year before the screening visit showing evidence of hepatitis (demonstrated by inflammation and/or fibrosis)~Exclusion Criteria:~* Previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis C~* Previous treatment with interferon or ribavirin~* Evidence of hepatic decompensation in cirrhotic subjects~* Subjects who have participated in a clinical study involving administration of an investigational drug within 2 months~* Part A only: subjects who have been on a HAART regimen within 12 weeks before study start

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Part A (Type: EXPERIMENTAL): The dose of ribavirin used (fixed versus weight-based) is region dependent
- Part B (Type: EXPERIMENTAL): The dose of ribavirin used (fixed versus weight-based) is region dependent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~• Moderate to severe glabellar frown lines at maximum frown (severity score of 2 or 3 on a 4-point facial wrinkle scale) as assessed by the investigator's rating: 0 = 'none', 1 = 'mild', 2 = 'moderate', 3 = 'severe'.~Main Exclusion Criteria:~* Marked facial asymmetry.~* Ptosis of eyelid and/or eyebrow.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- IncobotulinumtoxinA (Xeomin®/Bocouture®) (Type: EXPERIMENTAL): IncobotulinumtoxinA (Xeomin®/Bocouture®), 24 units; mode of administration: intramuscular injection.
- OnabotulinumtoxinA (Vistabel®) (Type: ACTIVE_COMPARATOR): OnabotulinumtoxinA (Vistabel®), 24 units; mode of administration: intramuscular injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: China Plant Sterol Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~The key inclusion criteria will be:~* Age between 18 and 65 years old (inclusive) at baseline~* Able to provide informed consent~* Usual diet that includes significant fat consumption at the main meals eaten each week and/or a history of hypercholesterolemia~* Participant is likely to comply with the study treatment during the study period~Exclusion Criteria:~Participants will be excluded on the basis of:~* Known serious gastrointestinal disease or other serious illness. Individuals with stable cardiovascular disease will, however, be eligible~* Known lactose intolerance or diet that excludes dairy products~* Known Sitosterolaemia (a very rare genetic condition causing very high blood sitosterol levels)~* Current hospitalisation~* Current use of drug with likely significant impact on gastro-intestinal absorption of cholesterol or plant sterol (e.g. ezetimibe, bile acid-binding resins, or orlistat)~* Participant is currently using or is planning to use non-trial plant sterol/stanol-containing products for the seven week study period~* Participation in another study within last 3 months~* Pregnant or planning to become pregnant in next three months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with schizophrenia for more than 1 year~* A total score in the Positive and Negative Syndrome Scale (PANSS) \< 120~* Signed informed consent~* Women must not be pregnant, breastfeeding, and if capable of pregnancy must practice an effective method of birth control~* Men must agree to use a double-barrier method of birth control~* Be medically stable on the basis of clinical laboratory tests, physical examination, medical history, vital signs, and electrocardiogram (ECG) Exclusion Criteria:~* A diagnosis other than schizophrenia, e.g., dissociative disorder, bipolar disorder, major depressive disorder, schizoaffective disorder, schizophreniform disorder, autistic disorder, primary substance-induced psychotic disorder, dementia-related psychosis~* Relevant history or current presence of any significant or unstable medical condition(s) determined to be clinically significant by the Investigator (ie, obesity, diabetes, heart disease etc)~* A diagnosis of substance dependence within 6 months before screening~* History of neuroleptic malignant syndrome (NMS) or tardive dyskinesia~* Clozapine use in the last 2 months when used for treatment-resistant or treatment-refractory illness~* Clinically significant findings in biochemistry, hematology, ECG or urinalysis results~* Any other disease or condition that, in the opinion of the investigator, would make participation not in the best interest of the patient or that could prevent, limit, or confound the protocol-specified assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Paliperidone palmitate 3-month (PP3M) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females who are 20 or over~* Patients who satisfy the classification criteria of Rheumatoid Arthritis according to American Colleague of Rheumatology (ACR 1987)~* Patients who are applicable to functional status I - III of American Colleague of Rheumatology~Exclusion Criteria:~* Patients who have autoimmune diseases other than rheumatoid arthritis or have significant secondary systematic disease caused by rheumatoid arthritis~* Patients who are currently participating in other clinical studies or receiving treatment for drugs not sold in the market or for experiment~* Patients who have significant other diseases that may affect the clinical trial when judged by the clinical trial Investigator~* In the opinion of the investigator, may put the patient at risk because of participation on the study or may influence the patients' ability to participate in the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HD203 (Type: EXPERIMENTAL): Subcutaneous injection (SC) HD203 25mg twice a week for 48 weeks
- Enbrel (Type: ACTIVE_COMPARATOR): Subcutaneous injection (SC) Enbrel® 25mg twice a week for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Project IMPACT: Improving Memory Performance by Applying Cognitive Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV infection~* currently on antiretroviral medications for \>3 months~* cocaine use as defined by crack/cocaine use in the past month, cocaine-type stimulant use disorder, and cocaine as the principal substance of abuse~* working memory impairment as defined by scoring \>1 standard deviation below the normative mean on at least 2 out of the 3 working memory tests~Exclusion Criteria:~* pregnancy~* English non-fluency or illiteracy~* \<8th grade education~* serious neurological disorders including HIV dementia, traumatic brain injury, severe mental illness, or acute psychiatric distress~* impaired mental status~* individuals who state they are planning to move away from the area within the next 3 months~* individuals without stable housing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Active Cognitive Training (ACT) (Type: EXPERIMENTAL): Participants will complete computerized games designed to enhance working memory. Participants will complete 48 training sessions over 8 weeks.
- Control Training (CON) (Type: SHAM_COMPARATOR): Participants will complete 48 training sessions over 8 weeks. The control games are not designed to enhance memory.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NIRS Measurement After SCP Block

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* all patients undergoing surgery under regional anaesthesia~Exclusion Criteria:~* patients refusal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supraclavicular Nerve Block (Type: None): Patients undergoing vascular surgery for creation or revision of an arterio-venous fistula. Intervention: supraclavicular plexus block for anaesthesia. NIRS measurement before and after brachial plexus block.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Osteoarthritis of the knee, hip, hand or spine which requires the use of medications for pain relief~Exclusion Criteria:~* Known allergies to the study drugs

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Computerized Tool for Preventing Prenatal Drinking

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* not pregnant in the last 6 months, drank alcohol in the past year, alcohol consumption was at risky levels,~Exclusion Criteria:~* not fluent in english or spanish,

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 44 Years
- Healthy Volunteers: t

Study Arms:
- e-SBI (Type: EXPERIMENTAL): Single session, Electronic SBI for risky alcohol use
- Control (Type: NO_INTERVENTION): Treatment as usual with only assessment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Weaning of Norepinephrine Guided by the Dynamic Arterial Compliance in Cardiac Surgery Post Operative.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Major patient ≥ 18 years~* Patient operated a cardiac surgery for myocardial revascularization (CABG surgery) or surgical correction of valvular or combined surgery (CABG and valve disease) or surgery the ascending aorta and cardiac surgery with vasoplegic syndrome treated by norepinephrine~* Signed consent~* Affiliation to social assurance~Exclusion Criteria:~* Permanent atrial fibrillation~* Treatment with dobutamine and/or epinephrine~* Pregnant woman~* Patient under guardianship or private public law~* Internal pacemaker~* Hypothermia~* Patient refusal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- administration of norepinephrine by dynamic elastance (Type: EXPERIMENTAL): The norepinephrine weaning strategy is based on an index that reflects the vasomotor tone: dynamic arterial elastance
- control administration of norepinephrine (Type: OTHER): The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete